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The Chinese herbal medicine, Huzhen Tongfeng Formula (HZTF), derived from traditional Chinese medicine (TCM) practice, has
recognized therapeutic benefits for gouty arthritis (GA). HZTF is currently in the late stage of approval process as a new anti-GA
drug application. However, the underlying mechanism of HZTF as an antigout medication is unclear. In this study, we combined
network pharmacology and experimental validation approaches to elucidate the mechanism of action of HZTF. First, the relative
drug-disease target networks were constructed and analyzed for pathway enrichment. Potential pathways were then validated by
in vitro and in vivo experiments. We found that 34 compounds from HZTF matched 181 potential drug targets. Topology
analysis revealed 77 core targets of HZTF, which were highly related to gout, following screening of KEGG pathway enrichment.
Further analysis demonstrated that the arachidonic acid metabolic pathway was the most relevant pathway involved in the
mechanism of HZTF. Validation experiments showed that HZTF significantly inhibited the inflammatory cell infiltration into
gouty joints, improved the swelling of affected joints, and increased the pain threshold. HZTF significantly reduced the
transcription and production of various cytokines and inflammatory mediators in vitro. In particular, cyclooxygenase (COX)-1,
COX-2, and 5-lipoxygenase were simultaneously downregulated. In conclusion, our study suggests that the antigout mechanism
of HZTF is associated with the inhibition of the arachidonic acid pathway, resulting in the suppression of inflammatory
cytokines and mediators. These findings extend our understanding of the pharmacological action of HZTF, rationalizing the
application HZTF as an effective herbal therapy for GA.
1. Introduction
Gouty arthritis (GA) is a common type of inflammatory dis-
ease resulting from a disturbance in purine metabolism,
which leads to the deposition of monosodium urate (MSU)
in joints or/and tissues. GA is characterized by red, tender,
hot, and tumid joints [1, 2]. Changes in life-style and dietary
structure in the last few decades have led to increasing
prevalence of gout worldwide [3–5]. Currently, there is no
cure for gout, and clinical treatments mainly aim at relieving
symptoms and preventing recurrence. Colchicine, glucocor-
ticoids, and nonsteroidal anti-inflammatory drugs (NSAIDs)
are mainly used to relieve acute GA, while allopurinol, benz-
bromarone, and other uric acid-lowering drugs are recom-
mended for chronic gout [6]. Although these medications
are relatively effective in controlling symptoms, side effects
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and relapse after withdrawal are problematic, leading to
negative impacts on clinical outcomes [6–9]. Therefore, there
is an unmet need to develop new antigout drugs that are
more efficacious with less side effects [10].
Traditional Chinese herbal medicine (TCM) has been
used for the prevention and treatment of gout for many cen-
turies in China [11, 12]. There is increasing evidence to show
that a number of TCMs have multiple effects, including anti-
inflammatory, analgesic, lowering hyperuricemic, and renal
protective effects, with the potential for wider use in the man-
agement of gouty conditions [11–16]. It has been reported
that TCM Huzhang Tongfeng Granule promotes the excre-
tion of urine uric acid and improves inflammatory symptoms
and signs of gouty arthritis patients in the acute phase [17].
The TCM preparation of Rebixiao granules was demon-
strated to be more effective in controlling recurrence, signs,
and the symptoms of patients with acute gouty arthritis com-
pared with diclofenac sodium [18]. Leucas zeylanica, a herb
commonly use in anti-inflammatory and antigout remedy,
was found to possess potent inhibitory effect on 5-LO,
mPGES-1, and XO [15]. More convincingly, randomized
clinical trials showed that TCM formulas Weicao capsule,
Chuanhu formula, and modified Simiao decoction were
more effective than the conventional antigout treatment,
with improvement in the adverse side effect profiles [19–21].
Huzhen Tongfeng Formula (HZTF) is a TCM formula
for GA, developed by our team at Jinan University based
on principles derived from traditional Chinese medicine
(TCM) practice [22]. It is composed of 4 Chinese herbs: Poly-
goni Cuspidati Rhizoma et Radix (PCRR, the root and rhi-
zome of Polygonum cuspidatum Sieb. et Zucc.), Ligustri
Lucidi Fructus (LLF, the fruit of Ligustrum lucidum Ait.),
Herba Plantaginis (HP, the dried whole grass of Plantago
asiatica L.), and Nidus Vespae (NV, the honeycomb of
Polistes olivaceus (De Geer), Polistes Japonicus Saussure, or
Parapolybiavaria Fabricius). Clinical data has shown that
HZTF significantly suppresses the inflammation and pain
in gouty arthritis patients, with a response rate of 96% [22].
No hypouricemic effect was found associated with the use
of HZTF in these studies. In a separate clinical study involv-
ing 287 GA patients, pain reduction was observed in 86.11%
of patients, and adverse events were recorded in only 2.78%
of patients. Since its prominent antigout effect with minimal
side effects and its suitability for long term use, HZTF has
been considered as a new antiarthritis drug by the National
Medical Products Administration (NMPA) of China under
the category of new TCM natural drug. Required clinical tri-
als (registered number: CTR20150783and CTR20131159)
have been completed. Although HZTF is now at its late stage
of NMPA approval process based on its improved efficacy in
GA patients, its mechanism of action as an anti-GA drug is
unknown.
Since HZTF is composed of multiple compounds, com-
piled from 4 TCM herbs, the usual approach employing the
paradigm of “one molecule, one drug” may not be a suitable
pathway to investigate the mechanism of action of HZTF.
Alternatively, a network pharmacological approach has the
potential to uncover the underlying complex relationship
between an herbal formula and the breadth of GA targets.
Previous studies have demonstrated network pharmacology
is capable of handling the holistic concept and syndrome dif-
ferentiation to discover the synergy between the active ingre-
dients [23–26]. In addition, a systematic and multilayered
“drug-gene-disease” network, designed to discover the syn-
ergy between the active ingredients and components of the
TCM, may further predict the pharmacological mechanism.
This approach would be helpful in the study of active sub-
stances, compatible regularity, and multichannel systemic
regulation mechanisms of Chinese medicinal compounds to
promote the development of new drugs for multimolecular
and multitarget therapy [24, 25].
In this study, we combined network pharmacology and
experimental validation approaches, as outlined in Figure 1,
to illustrate the mechanism of action of HZTF, to uncover
the compound–compound targets and compound-disease
target networks, and the potential signaling pathways
involved in the pharmacological action of HZTF as antigout
therapy.
2. Materials and Methods
2.1. HZTF Ingredients and Related Targets Screening. Com-
pounds of PCRR, LLF, and HP were obtained according to
selection criteria ðdrug − likeness ðDLÞ ≥ 0:18 and oral
bioavailability ðOBÞ ≥ 30) from the TCM Systems Pharma-
cology Database and Analysis Platform (TCMSP)1 and
related targets [27]. In addition, the ingredients of NV
obtained from the Reference Handbook for Chinese Pharma-
copeia (Volume I)-Modern Analysis Technology for Evaluat-
ing the Quality of Traditional Chinese Medicine. The
potential targets were obtained from Swiss Target Predic-
tion2. By using the platform to query the corresponding
target of the compound, Uniprot normalizes the gene
information and eliminates the gene without the human
sample Uniprot ID.
2.2. Collection of Potential Targets for Gout. Gout-associated
targets were obtained from the following databases using
“Gout” as the keyword: [1] Therapeutic Targets Database3,
[2] DrugBank4, [3] Comparative Toxicogenomics Database5,
[4] The Online Mendelian Inheritance in Man (OMIM)
database6, and PubMed7. The platform was used to search
for “gout”-related target genes, Uniprot standardized gene
information, and the gene without the human sample,
Uniprot ID, was excluded.
2.3. Systems Network Construction and Analysis. Protein-
protein interactions greatly influence the biological process
of the organism, including signal transduction, immunoreg-
ulation, and cell proliferation [28]. To better elucidate the
relationship between HZTF and gout, a compound-target-
disease network was built with the protein-protein interac-
tion (PPI) information, which was visualized and analyzed
by Cytoscape v.2.5.1 (National Institute of General Medical
Sciences, United States). The network topology parameters,
including Degree, Betweenness Centrality, Average Shortest
Path Length, and Closeness Centrality, were determined
[29]. The degree of a node in the network indicates the
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number of nodes directly interacting with the node. The
greater the degree, the more biological functions that node
participates in, and the greater its importance in the network.
2.4. Gene Ontology and Pathway Analysis. To analyze and
obtain the main function and the enriched-pathway of the
target genes, Gene Ontology (GO) and pathway analysis were
performed through the Database for Annotation, Visualiza-
tion and Integrated Discovery (DAVID 6.8) [23, 30]. Briefly,
a list of target gene names was entered into the database. The
species was then defined as “Homo Sapiens”; the target gene
name was corrected to the official name (“official gene sym-
bol”); the threshold was set to P < 0:05 for GO biological pro-
cess and KEGG pathway enrichment analysis. Correlation
analysis results were obtained with P < 0:05 as the screening
condition.
2.5. Animals and Drug. Male Japanese big ear white rabbits
(weight 3:0 ± 0:5 kg) were purchased for the GA model
(described in 2.6) from the Department of Laboratory Ani-
mal Science, Tongji Medical College, Huazhong University
of Science and Technology, China (Certification No: YDZ
19-025). Male Kunming mice (weight 25 ± 2 g) were pur-
chased from the Henan Experimental Animal Center, China
(Certification No: 410115). Rabbits and mice were housed in
a SPF-grade environment with water and food, at a constant
temperature (23 ± 2°C), and humidity of 60 ± 5% in the
Experimental Center of Jinan University.
HZTF was provided by the Guangzhou Jinan Biomedi-
cine Research and Development Center Co., Ltd., (Lot:
030901). Monosodium urate crystal, xylene, and antimony
potassium tartrate were purchased from Shanghai Yuanye
Bio-Technology Co., Ltd, China. Dulbecco’s modified Eagle’s
medium (DMEM) (Gibco BRL, Grand Island, NY, USA),
fetal bovine serum (FBS) (Guangzhou Juyan Co., Ltd.,
China), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-nyltetrazo-
lium bromide (MTT) (Guangzhou Juyan Co.,Ltd.,China),
and uric acid (SERVA, Germany) were used in this experi-
ment. All other solvents and chemical reagents used in this
study were of analytical grade and were purchased locally.
2.6. MSU Crystal-Induced Inflammation in Rabbits. All
procedures were performed based on methods described
previously [31], with slight modifications. Rabbits were ran-
domly divided into 5 groups (control, model, and HZTF at
high, median, and low doses). HZTF groups were orally
administered different dosages once daily for 5 days. Thirty
minutes after the 5th administration, animals were injected
0.3mL MSU crystal suspension (100mg/mL) at the medial
side of the right ankle joint of the hind limb for the model
group and HZTF groups, respectively. Rabbits were sacri-
ficed 5h after injection. Joint effusion was collected from
anatomical knee joints, and white blood cell counts were
measured.
2.7. Ear Edema Induced by Xylene in Mice. All procedures
were executed based on methods described by Chen and
HZTF Gout
Compound targets Disease targets








In vivo studies In vitro studies
HZTF regulated arachidonic
acid metabolic pathway and
inflammatory mediators
Figure 1: Flowchart of study design—based on an integration strategy of network pharmacology and experimental validation.
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colleagues [32], with modifications. The HZTF groups were
orally administered different dosages once daily for 5 days.
Thirty minutes after the fifth administration, 50μL of xylene
was smeared on the surfaces of the right ear. After 1 h, mice
were sacrificed, and both ears of each animal were collected.
Using a 6mm diameter puncher, round pieces of ear tissues
were punched and weighed. The difference in weight between
the left and right ears was considered to represent the degree
of swelling. The study was approved by the institutional
research ethics committee of the Laboratory Animal Center
of Henan Province.
2.8. Hot Plate Test in Mice. To assess the analgesic effect of
the drug, mice were orally administered different dosages of
HZTF once daily for 5 days. The nociceptive threshold was
evaluated as the reaction time to the hot plate (55 ± 0:5°C).
The response was measured as the time to licking of the fore-
paws or hind paws by mice. The maximal cutoff time was set
to 60 s to reduce injury to the mouse. At 30, 60, and 90min
after the fifth administration, the antinociceptive effect of
HZTF was determined [33]. The study was approved by the
institutional research ethics committee of the Laboratory
Animal Center of Henan Province.
2.9. Antimony Potassium Tartrate-Induced Abdominal
Writhing Test in Mice. For the antimony potassium
tartrate-induced writhing experiment, mice were orally
administered different dosages of HZTF once daily for 5
days. Thirty minutes after the final administration, mice were
injected i.p. with 0.05% antimony potassium tartrate
(0.1mL/10 g). The number of abdominal constrictions was
recorded for 20min after the injection [34]. The study was
approved by the Ethics Committee of Zhengzhou University.
2.10. Cell Culture. The murine macrophage cell line,
RAW264.7, was obtained from the American Type Culture
Collection (Manassas, VA, USA) and was propagated in
DMEM high glucose medium supplemented with 10%
heat-inactivated calf serum. Cells were cultured at 37°C in a
5% CO2 incubator for various in vitro studies as detailed
below.
2.11. MTT Assay. The cytotoxic effect of HZTF on
RAW264.7 cells was tested using the MTT assay following
the Mosmann method [35]. Briefly, RAW264.7 cells were
first plated in 96-well plates overnight; the medium was then
aspirated, and subsequently, cells were treated with different
concentrations of HZTF for 24 h. After the medium was
removed, cells were washed and incubated with MTT for
4 h. The medium was then removed, and 100μL of DMSO
was added. Absorbance was measured at 570 nm [36].
2.12. LPS-Induced Cell Inflammation Model. RAW264.7
mouse macrophage cells were cultured in DMEM containing
10% FBS at 37°C with 5% CO2 in the air. To evaluate the anti-
inflammatory activities of HZTF, RAW264.7 mouse macro-
phages were cultured in 6-well plates overnight to reach
80% confluence. Cells were pretreated with different concen-
trations of HZTF (12.5, 25, and 50μg/mL) or the positive
control, dexamethasone (10μg/mL). Following addition of
lipopolysaccharide (LPS 100ng/mL) and incubation, culture
media and cells were collected for further experimentation.
2.13. RNA Isolation and Real-Time PCR. After 17 h of incu-
bation with LPS and HZTF, cells were washed with 1× PBS.
TRIzol reagent was then added for total RNA isolation. The
IScript Advanced cDNA synthesis kit was used to reverse
transcribe cDNA. Real-time PCR was performed on a Bio-
Rad Real-Time PCR System using SYBR Green PCR Master
Mix. Mouse specific primers, detailed in Table 1, were syn-
thesized by Sangon Biotech (Shanghai, China). The following
amplification parameters were used for PCR: 50°C for 2min,
95°C for 10min, and 40 cycles of amplification at 95°C for
15 s and 60°C for 1min. All experiments were performed in
triplicate.
2.14. Measurement of Inflammatory Cytokines and
Mediators. RAW264.7 cells were plated at a density of 5 ×
105/mL on 6-well plates and pretreated with different
concentrations of HZTF 1h before treatment with LPS
(100 ng/mL). After one day of incubation, the culture super-
natant was collected to quantify the cytokine and NO level.
Cytokine concentration was quantified using the ELISA kits
from NEOBIOSCIENCE; optical density at 450nm was
determined using a microplate reader (ELx800, BioTek,
USA). NO was quantified by the Griess reaction (Nitrate/Ni-
trite Assay Kit, Beyotime, Shanghai, China), and optical
density was determined using a microplate reader set at
540 nm. All experiments were performed in triplicate.
2.15. Imaging and Quantification of Intracellular Reactive
Oxygen Species (ROS) Generation. Briefly, dichlorodihydro-
fluorescein diacetate (DCFH-DA) was hydrolyzed in the cell
by esterase to form DCFH, which is oxidized by ROS to gen-
erate fluorescent DCF. The RAW264.7 cell line used in this
experiment was seeded onto 6-well plates at a density of 1
× 106/well. Overnight, the cells were pretreated with differ-
ent concentrations of HZTF for 1 h and exposed to LPS (final
concentration, 100 ng/mL) and incubated in a CO2 incubator
for 24 h. The plates were washed 3 times with free-FBS
DMEM. DCFH-DA (diluted in DMEM, final concentration,
10μM) was then added and incubated for 1 h in the dark.
Free dye was eluted with DMEM, and the fluorescence was
measured using a fluorimeter at 488nm excitation and emis-
sion at 520 nm (Ti-E, Nikon, Japan) [37]. All experiments
were performed in triplicate.
2.16. Western Blot Analysis. Proteins in the RAW264.7 mac-
rophages were extracted and adjusted to achieve the same
volume and equal concentration. The protein extracts were
subjected to 10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and transferred to polyvinylidene fluoride
(PVDF) membranes. PVDF membranes were blocked with
5% bovine serum albumin in tris-buffered saline-Tween 20
(TBST) buffer (137mM NaCl, 20mM Tris, pH7.6, with
0.1% Tween 20) for 60min at room temperature. The PVDF
membrane was washed 3 times with TBST for 10min per
wash. The membranes were then incubated overnight at
4°C with antiphospholipase A2 (cPLA2) antibody (Santa
Cruz, CA, USA) at 1 : 500, anti-COX-2 antibody (Santa Cruz)
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at 1 : 500, anti-COX-1 antibody (Genetex, TX, USA) at
1 : 1000, antiarachidonate 5-lipoxygenase activating protein
(FLAP) antibody (Genetex) at 1 : 1000, and antiarachidonate
5-lipoxygenase (5-LO) antibody (CST, MA, USA) at 1 : 1000.
After 3 washes with TBST, the membranes were incubated
with secondary antibody (1 : 7000) in TBST with 5% bovine
serum albumin for 1 h before 3 [16] additional washes with
TBST. Western blots were developed on films using the
enhanced chemiluminescence technique. Quantification of
bands was determined by densitometry analysis using Tano-
nImagine. Data were normalized using β-actin (1 : 2000)
(CST) as an internal control [29]. All experiments were
performed in biological triplicate.
2.17. Statistical Analysis. All data are expressed asmean ± SD
. Statistical analysis was performed using GraphPad Prism 7
(San Diego, CA, USA). Data among the groups were
analyzed with ANOVA. A P value < 0.05 was considered
statistically significant.
3. Results
3.1. Identification of Active Compounds in HZTF and HZTF
Targets. Using a network pharmacology approach, com-
pounds/ingredients from each herbal medicine of the HZTF
used for target identification were searched and selected
based on published studies and relevant databases by the spe-
cific ADME method. As shown in Table 2, 34 active com-
pounds from herbs of HZTF were identified and included
in the study, of which, 10 compounds from PCRR, 7 from
HP, 8 from LLF, and 9 from NV. Furthermore, 181 drug tar-
gets associated with the 34 active ingredients from HZTF
were obtained (details in Figure 2 and Supplementary
Table S1). The graph of the compound–target interactions
was constructed, consisting of 212 nodes and 440 edges.
3.2. Construction and Analysis of Compound Target–Disease
Target Network. Based on available data from various gouty
disease databases, 224 gout-related targets were identified (Sup-
plementary Table S2). By mapping the compound targets with
these gout-related targets, 28 common targets were identified.
These 28 targets and their related targets were used to build a
PPI network comprising 317 nodes and 1515 edges
(Figure 3). Average values for “Degree,” “Closeness,” and
“Betweenness” for nodes were 6, 0.3092, and 0.0015,
respectively. By screening according to specific conditions
(“Degree” ≥ 12, “Closeness” ≥ 0:309, “Betweenness” ≥ 0:002),
77 important targets were obtained, which were used for
further analysis (Supplementary Table S3).
3.3. Analysis of Function and Pathway Enrichment. For GO
enrichment analysis, 77 important targets described above
were entered into the DAVID database for further analysis.
As a result, 153 entries (Supplementary Table S4) were
found to be enriched, including various categories such as
positive regulation of transcription from RNA polymerase
II promoter, inflammatory response, extracellular space,
DNA binding, and cytokine activity. An overview of the
biological process, cellular components, and molecular
function categories was illustrated with the top 10 enriched
terms using a bubble (Figures 4(a)–4(c)). Further KEGG
pathway enrichment analysis demonstrated that 11
pathways were identified as significant and meaningful
(P < 0:05) pathways, including arachidonic acid
metabolism, cytokine-cytokine receptor interaction, NOD-
like receptor signaling pathway, and JAK-STAT signaling
Table 1: Primers used in Real-Time PCR.














6,8-Dihydroxy-7-methoxyxanthone, physovenine, picralinal, physciondiglucoside, torachrysone-8-
O-beta-D-(6′-oxayl)-glucoside, rhein, sitosterol, (+)-catechin, luteolin, quercetin
Herba Plantaginis 7 Dinatin, baicalein, baicalin, sitosterol, 6-OH-luteolin, stigmasterol, luteolin
Ligustri Lucidi Fructus 8 Sitosterol, kaempferol, taxifolin, lucidumoside D, lucidumoside D_qt, eriodictyol, luteolin, quercetin
Nidus Vespae 9
Sitosterol, daucosterol, stearic acid, cerotic acid, protocatehuic acid, 4-hydroxybenzoic acid, caffeic
acid, thymidine, p-dihydroxybenzene
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pathway, as shown in Figure 4(d) and Supplementary
Table S4.
3.4. HZTF Ameliorated Acute Gout Related Inflammation In
Vivo. Typical clinical presentations of acute gout mainly
include articular and periarticular swelling and pain and
rapid recruitment of innate immune cells into the synovium.
To assess the therapeutic effect of HZTF on acute gout, the
anti-inflammatory, detumescence, and analgesic effects of
HZTF were examined. Following treatment with HZTF for
5 days, animals’ leucocyte count in the joint effusion, ear
swelling, and pain response were evaluated. We found that
the number of white blood cells (WBC) in the synovium of
the gout models and the HZTF groups was significantly
increased compared with the control. HZTF treatments sig-
nificantly lower the WBC in the synovium (Table 3). As
shown in Table 4, HZTF inhibited ear swelling in a dose-
dependent manner, ranging from 17.7% to 56.9%, compared
to that for the untreated group. In the hot plate test in mice,
HZTF significantly extended the time to withdraw from the
hot plate compared to the control group. Of noted, the max-
imum protection of HZTF was displayed at 60min after drug
administration at a dose of 1.00g/kg (Table 5). We also
adopted the antimony potassium tartrate-induced abdominal
writhing test to verify the antinociceptive effect of HZTF.
The results indicated that HZTF dose-dependently decreased
the number of writhing episodes in mice in comparison to
the model group (Table 6).
3.5. Effects of HZTF on ROS Production. To explore whether
HZTF has an effect on oxidative damage, the level of ROS in
RAW264.7 cells was measured using intracellular ROS probe,
H2DCF-DA. As shown in Figure 5, we found that HZTF sig-
nificantly (P < 0:01) suppressed the accumulation of intracel-
lular ROS at all dosages tested (12.5, 25, and 50μg/mL),
compared to the control group.
3.6. HZTF Suppressed mRNA Expression of Inflammatory
Cytokine and Mediators. To identify suitable doses and eval-
uate the effect of HZTF in the LPS-induced inflammation
experimental model, the cytotoxicity of HZTF was examined.
As shown in Figure 6(a), no obvious toxicity was observed in
a serial concentration of HZTF from 6μg/mL to 400μg/mL.
Hence, 12.5 (low dose), 25 (medium dose), and 50μg/mL
(high dose) were determined as the treatment doses for our
study.
Figure 2: The compound–compound target network. Red, green, and purple circles represented the herbs composing HZTF, active
compounds from the herbs, and targets of the compounds, respectively. The size of purple circles represented node degree value.
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It is widely acknowledged that mass inflammatory
cytokine and mediators demonstrate a high expression
level after inflammation induction, such as interleukin-1β
(IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α
(TNF-α), cyclooxygenase-2 (COX-2), and inducible nitric
oxide synthase (iNOS) [38–40]. Through pathway enrich-
ment, the results revealed the strong regulation effect of
HZTF on the arachidonic acid pathway. In the early
mechanism study of HZTF on LPS-induced inflammation,
the mRNA expression levels of IL-1β, IL-6, TNF-α,
cyclooxygenase-1 (COX-1), COX-2, prostaglandin E syn-
thase 2 (PGES2), and iNOS were measured. As shown in
Figures 6(b)–6(f), LPS induced a significant increase in
the mRNA expression of IL-1β, IL-6, TNF-α, COX-1,
COX-2, PGES2, and iNOS, which indicated the occurrence
of inflammation. Meanwhile, the LPS-induced inflamma-
tion was treated with different doses of HZTF. The afore-
mentioned mRNA expression levels of the inflammatory
cytokines and mediators were remarkably inhibited in a
concentration-dependent manner. These results prelimi-
narily indicate that HZTF could inhibit LPS-induced
inflammation.
3.7. HZTF Decreased Production of Cytokine and Other
Inflammatory Mediators. To examine the effects of HZTF
on the production of inflammatory cytokine and mediator
in RAW264.7 cells stimulated by LPS, the concentrations
of nitric oxide (NO), IL-1β, IL-6, TNF-α, prostaglandin
E2 (PGE2), and leukotriene B4 (LTB4) in the culture
supernatant of RAW264.7 macrophages were measured
by ELISA. The results showed that levels of NO, IL-1β,

















































Figure 3: The protein-protein interaction network. Yellow diamonds and red circles represented the targets of compounds and disease,
respectively. Green diamonds and green circles indicated 28 common targets. The size of circles and diamonds indicated node degree value.
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elevated (P < 0:01 or P < 0:001) comparing relative to the
control group. However, these proinflammatory effects
were reversed by HZTF treatment at the doses tested
(Figure 7).
3.8. HZTF Modulated the Pathway of Arachidonic Acid. As
shown in Figure 8, HZTF exhibited a significant inhibitory
effect on COX 1 (Figures 8(a) and 8(d)), COX 2






















hsa04920: Adipocytokine signaling pathway
hsa04660: T cell receptor signaling pathway
hsa04630: Jak-STAT signaling pathway
hsa04621: NOD-like receptor signaling pathway
hsa04620: Toll-like receptor signaling pathway
hsa04210: Apoptosis
hsa04060: Cytokine-cytokine receptor interaction
hsa03320: PPAR signaling pathway
hsa00590: Arachidonic acid metabolism
hsa00380: Tryptophan metabolism
hsa00150: Androgen and estrogen metabolism
(d)
Figure 4: DAVID database enriched pathways and GO entries. (a) GO enrichment entries of the biological process showing the top 10. (b)
GO enrichment entries of cellular components (the top 10). (c) GO enrichment entries of molecular function (the top 10). (d) KEGG pathway
enrichment entries (P < 0:05).
Table 3: Effects of HZTF on white blood cells in rabbit knee joint
effusion induced by MSU (n = 8).
Groups Doses (g/kg/d) WBC (×104/mm3)
Model — 11:40 ± 3:68
HZTF-L 0.20 9:46 ± 1:33∗
HZTF-M 0.35 8:16 ± 2:54∗∗
HZTF-H 0.70 7:16 ± 1:11∗∗∗
∗P < 0:05, ∗∗P < 0:01, ∗∗∗P < 0:001, compared with the model group. HZTF-
L: low dose of HZTF; HZTF-M: medium dose of HZTF; HZTF-H: high dose
of HZTF.
Table 4: Effects of HZTF on xylene-induced ear swelling in mice
(n = 10).
Groups Doses (g/kg/d) Ear swelling (mg) Inhibition (%)
Model — 10:2 ± 3:8 —
HZTF-L 0.25 8:4 ± 2:6∗ 17.7
HZTF-M 0.50 5:8 ± 1:9∗∗ 43.1
HZTF-H 1.00 4:4 ± 1:6∗∗∗ 56.9
∗P < 0:05, ∗∗P < 0:01, ∗∗∗P < 0:001, compared with the model group. HZTF-
L: low dose of HZTF; HZTF-M: medium dose of HZTF; HZTF-H: high dose
of HZTF.
Table 5: Effects of HZsTF on the time to respond in the hot-plate




Time to response (s)
30min 60min 90min
Normal — 16:6 ± 1:9 17:0 ± 2:3 17:8 ± 2:1
HZTF-L 0.25 22:5 ± 3:6∗∗ 27:1 ± 3:0∗∗ 23:0 ± 3:3∗∗
HZTF-M 0.50 22:9 ± 4:4∗∗ 29:6 ± 4:4∗∗ 24:7 ± 4:2∗∗
HZTF-H 1.00 27:4 ± 3:1∗∗ 36:8 ± 4:3∗∗∗ 27:2 ± 3:2∗∗
∗∗P < 0:01, ∗∗∗P < 0:001, compared with the normal group. HZTF-L: low
dose of HZTF; HZTF-M: medium dose of HZTF; HZTF-H: high dose of
HZTF.
Table 6: Effects of HZTF on writhing response induced by
antimony potassium tartrate in mice (n = 10).
Groups Doses (g/kg/d) Number of writhing Inhibition (%)
Model — 51:1 ± 11:4 —
HZTF-L 0.25 39:5 ± 6:4∗∗ 22.7
HZTF-M 0.50 31:3 ± 5:2∗∗∗ 38.7
HZTF-H 1.00 23:2 ± 6:4∗∗∗ 54.6
∗∗P < 0:01, ∗∗∗P < 0:001, compared with the model group. HZTF-L: low
dose of HZTF; HZTF-M: medium dose of HZTF; HZTF-H: high dose of
HZTF.
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RAW264.7 cells stimulated by LPS, as demonstrated by
Western analysis. However, it appeared that similar effect
did not apply to the cPLA2 and FLAP expression
(Figures 8(a), 8(b), and 8(e)).
4. Discussion
HZTF is an effective, but relatively new, TCM-based anti-GA
therapy. In this study, in order to uncover the underlying
mechanism of action of this formula HZTF in which multiple
compounds are involved, we chosen to combine a network
pharmacology approach with a focused experimental valida-
tion design (Figure 1).We successfully identified the core active
ingredients of HZTF, constructed the compound target-disease
target network, and predicted the potential metabolic pathway
enrichment by mapping the compound targets with the disease
targets. Importantly, we validated the predicted pathways
involved in the pharmacological actions of HZTF, supporting
that HZTF significantly suppressed the metabolism of arachi-
donic acid by inhibiting COX1, COX2, and 5-LO, leading to
anti-inflammatory and analgesic effects for GA.
As stated previously, HZTF formula was developed based
on the principles/theory used in TCM practice emphasizing
treatment outcome. Despite established efficacy, very little
information is available on the underlying mechanism of
HZTF used as anti-GA therapy. Network pharmacology has
recently been used as an effective tool to predict the underly-
ing mechanism of TCM herbs or formula [23, 26]. Hence, in
this study, we adopted a similar approach to examining the
mechanism of action of HZTF. The DAVID database was
used to predict pathways that are closely related to gouty
disease, and the results showed that arachidonic acid metab-
olism, cytokine-cytokine receptor interaction, NOD-like
receptor signaling pathway, and JAK-STAT signaling path-
way are the most relevant predicted pathways. These results
are in agreement with previously published data [41–44].
The most important finding of note in this study is the dis-
covery that the arachidonic acid metabolism pathway is the
number 1 shared signaling pathway of HZTF in GA as shown
in Figure 4(d). Importantly, the inhibition of HZTF on
arachidonic acid metabolism pathway was subsequently
validated by a series of in vitro experiments.
Arachidonic acid is metabolized via catalysis of two
enzymes COX and 5-LO. Metabolism through COX leads
to formation of prostaglandins, causing pain, vasodilation
(swelling and redness), and fever. When 5-LO is combined
with its activating protein, FLAP, arachidonic acid undergoes
a series of transformations and finally forms leukotriene, pro-
moting neutrophil chemotaxis [45–47]. Under the gouty
condition, sodium urate crystals are deposited on the joints,
and inflammatory cells are recruited around them; ultimately
inflammatory mediators such as PGE2, LTB4, and IL-1β are
released causing symptom-related inflammatory reactions
and pain responses [48]. PGE2 and LTB4 are the end prod-
ucts of the COX and 5-LO branches of arachidonic acid,
respectively, and are closely related to the symptoms at gouty
sites [49]. At the cellular level, we showed that HZTF signif-
icantly downregulated products derived from both COX
(PGE2) and 5-LO (example being LTB4). We believe that
the downregulation observed contributes to the efficacy of
HZTF. Further, molecular biology experiments revealed that
HZTF has significant inhibitory effects on the upstream pro-
teins PGE2 and LTB4, as well as COX-1, COX-2, and 5-LO.
The identified active ingredients from HZTF provide strong
support for the HZTF’s inhibitory effect on the arachidonic
acid metabolism. It has been shown that ingredients such as
quercetin, catechin, luteolin, rhein, sitosterol, baicalein, and
stigmasterol have a suppressive effect on COX [50–53], while
compounds including baicalein, quercetin, taxifolin, and
caffeic acid were reported to downregulate 5-LO [54–57].
HZTF treatment leads to low-level recruitment of white
blood cells in the synovium, significant antiswelling effect,
and improvement of the pain threshold in the GA models.
These phenomena are the direct result of the inhibition of
Control























































Figure 5: Effects of HZTF on LPS-induced ROS accumulation in RAW264.7 cells. After pretreatment with HZTF (12.5, 25, and 50μg/mL) or
positive drug (dexamethasone at 10μg/mL) treatment for 2 h then treatment with LPS (100 ng/mL) for 24 h, cells were incubated with 10μM
DCFH-DA for 30min. (a) The fluorescent microscopy showing production of intracellular ROS (scale bar: 50 μm). (b) The relative
fluorescence intensity was analyzed by the Image J software (version 1.51). Data were presented as the mean ± SD (n = 3). ###P < 0:001,
compared with the control group; ∗∗P < 0:01, ∗∗∗P < 0:001, compared with the LPS group.
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Figure 6: Anti-inflammatory effect of HZTF in LPS-stimulated RAW264.7 macrophages. (a) Cell viability as determined by the MTT assay.
The relative mRNA expression of (b) IL-1β, (c) IL-6, (d) TNF-α, (e) COX-2, (f) COX-1, (g) iNOS, and (h) PGES2, following pretreated with
different doses of HZTF for 2 h and stimulated by LPS (100 ng/mL) for 6 h. Results were presented as means ± SD (n = 3). ###P < 0:001
compared with the control group; ∗P < 0:05, ∗∗P < 0:01, and ∗∗∗P < 0:001 versus the LPS group.
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the arachidonic acid metabolism pathway, leading to reduced
formation of prostaglandins and leukotriene. The antioxida-
tive effects of HZTF may partially account for the underlying
mechanism. NO and ROS, which are affected by the activa-
tion of the arachidonic acid pathway [58, 59], were also
significantly inhibited by HZTF as demonstrated in our
in vitro experiments.
Although many previous studies have reported that the
arachidonic acid metabolism pathway plays an important
role in the pathogenesis of gout [60–62], very few herbal-
based antigout therapies have been reported to have a mech-
anism of action associated with the inhibition of arachidonic
acid pathway. Napagoda and colleagues showed that lipo-
philic extracts of Leucas zeylanica inhibited 5-LO, micro-
somal prostaglandin E2 synthase-1, and xanthine oxidase,
rationalizing its application as anti-inflammatory and antig-
out remedy [15]. It appears that the reported underlying
mechanisms for other TCM-based antigout therapies are
mainly related to the inhibition of the NLRP3 pathway [13,
43, 63].
Currently, NSAIDs are the commonly used and recom-
mended first-line therapy for GA patients [64]. It is well
known that NSAIDs exert their pharmacological actions by



























































































































































































































Figure 7: Effects of HZTF on the production of IL-1β, IL-6, TNF-α, PGE2, and LTB4 in RAW264.7 cells under stimulation of LPS.
RAW264.7 cells were pretreated with HZTF for 1 h and then induced with LPS (100 ng/mL) for 24 h. The concentration of NO (a) was
determined by the Griess assay. (b) IL-1β, (c) IL-6, (d) TNF-α, (e) PGE2, and (f) LTB4 level in the cell culture supernatant were
quantified using an ELISA kit. The data were presented as means ± SD (n = 3). ##P < 0:01, ###P < 0:001 compared with the control group; ∗
P < 0:05, ∗∗P < 0:01, and ∗∗∗P < 0:001 versus the LPS group.
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formation of prostaglandins. However, the common side
effects of NSAIDs, such as gastrointestinal and renal toxic-
ities, greatly limit its clinical use as the long term therapy
for GA patients [65]. In contrast, no gastrointestinal adverse
effect has been observed in any clinical trials using HZTF.






























































































































































































































Figure 8: Alterations of the arachidonic acid (AA) pathway in the RAW264.7 cells following HZTF treatment: (a) expression of cPLA2, COX-
2, COX-1, FLAP, and 5-LO by Western blot analysis; (b) the cPLA2/β-actin ratio; (c) the COX-2/β-actin ratio; (d) the COX-1/β-actin ratio;
(e) FLAP/β-actin ratio; (f) the 5-LO/β-actin ratio. Sample loading was normalized by β-actin. n = 3; ##P < 0:01,###P < 0:001 vs. control group;
∗∗P < 0:01,∗∗∗P < 0:001 vs. LPS-induced group.
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HZTF, HZTF blocks all the enzyme limited metabolism
pathways by blocking both COX and 5-LO, while NSAIDs
only suppress COX. Previous studies demonstrated that by
individually inhibiting COX-2, arachidonic acid metabolism
would be shunted in the 5-LO pathway, producing increased
amounts of 5-LO products such as leukotriene, leading to
unwanted effects of NSAIDs. Coinhibition of COX and 5-
LO would remove this shunt effect [66]. Our study provides
direct evidence that HZTF simultaneously downregulates
COX and 5-LO, which blocks the shunt effect in arachidonic
acid metabolism. We speculate that this unique effect of
HZTF may explain the reduced side effect profile of HZTF
observed in the treatment of GA.
In addition to the inhibition of the arachidonic path-
way, we found that HZTF has a broad anti-inflammatory
property inhibiting a number of other inflammatory
cytokine and mediators including IL-1β, IL-6, TNF-α,
and iNOS, at both transcriptional and protein levels
(Figures 6 and 7). Although we did observe a significant
inhibition of TNF-α mRNA and protein in the experi-
ments, the magnitude of TNF-α protein decrease in the
cell culture supernatant (Figure 7(d)) was far less than that
of mRNA (Figure 6(d)). This may be related to the timing
of the experiment whereby the changes in TNF-α protein
did not tightly correlated with the mRNA level within
the experimental time frame. As shown in other studies,
the level of TNF-α mRNA transcription did not always
correlated to the release of TNF-α in RAW264.7 cell [67].
In general, the mechanism of action for any TCM recipe
is complex and difficult to elucidate, due to multiple ingredi-
ents involved. In this study, we have successfully demon-
strated that the key mechanism of HZTF as an anti-GA
therapy is the inhibitory effect of HZTF on the metabolism
of arachidonic acid pathway and on inflammatory mediators
at both translational and protein levels, thus rationalizing the
use of HZTF as an anti-GA therapy. This was completed
through pathway prediction using network pharmacology
and then in vitro and in vivo experimental verification. The
possible mechanism and signaling pathway of HZTF are
summarized in Figure 9.
There are some limitations in this study. Firstly, many
active components of HZTF identified have anti-
inflammatory effects and other related pharmacological
actions; however, the importance of specific ingredients in
this therapy remains unknown. Secondly, this study only
explores the impact of HZTF on the key targets of the arachi-
donic acid pathway and gene and protein expression of some
inflammatory mediators. Other downstream targets have not
been investigated. Therefore, in the future, more in-depth
studies exploring the detailed mechanism of action for HZTF
are required to advance the understanding of the pharmacol-
ogy of HZTF and to optimize the clinical application of
HZTF therapy.
5. Conclusion
In conclusion, we have successfully used the network
pharmacological analysis method combining “wet-
laboratory” experiments to explore the pharmacological
mechanisms of HZTF, a patented TCM formula for GA.
Our study predicts the active ingredients in the 4 herbs
of HZTF and the connection between multiple targets of
the ingredients in herbal formula and multiple targets of
GA. Based on the results of pathway enrichment, we
verified that HZTF relieves the inflammatory response in
GA by suppressing the arachidonic acid pathway and pro-
duction of inflammatory cytokines and mediators such as
NO, IL-1β, IL-6, TNF-α, PGE2, and LTB4. The superior
clinical profile of HZTF featuring minimal adverse effects
may be related to the characteristics of HTZF that simul-
taneously suppresses COX1, COX2, and 5-LO, delineating
the differences in the mechanisms of action of NSAIDs
and other herbal formulas.
Inflammation













Figure 9: Overview of mechanism of HZTF on GA.
14 Mediators of Inflammation
Data Availability
The data used to support the findings of this study are
available from the corresponding author upon request.
Conflicts of Interest
The authors declare that there is no conflict of interest
regarding the publication of this paper.
Authors’ Contributions
YigL, YW, and ZPW designed and supervised the study. JD
and CC analyzed the data and wrote the first draft of manu-
script. JD and ZCW mainly performed the experiments. ZZ,
YifL, and ZS helped the experiments. JD and YigL revised
and finalised the manuscript.
Acknowledgments
This work was supported by research grants from the Guang-
dong Provincial Engineering Center of Topical Precise Drug
Delivery System and the Science and Technology Projects of
Guangdong Province (2016A040402033); the National Engi-
neering Research Center for Modernazation of Traditional
Chinese Medicine-Sub Center of Artemisiae Argyi Folium;
the Tianhe District Science and Technology Plan Project-
Key Technologies Project (2018BY003); the Introduction of
Leading Talents Program; the Swan Project Innovation Team
Plan of Huizhou City; the Key Laboratory of Bioengineering
Drugs of Guangdong Province of China; the Innovation
Strong School Project of Department of Education of Guang-
dong Province and Guangdong Pharmaceutical University,
China; and the Talent Training Program of Guangdong
Province Joint Training Graduate Demonstration Base.
We thank Professors Qingduan Wang and Jinhua Jiang
of Medical College of Zhengzhou University for their assis-
tance with the animal study and data collection.
We would like to thank Editage (http://www.editage.cn)
for English language editing.
Supplementary Materials
Table S1: detailed information of targets for HZTF com-
pounds. Table S2: list of gout-related targets from disease
databases. Table S3: list of 77 core targets extracted from a
protein-protein interaction network. Table S4: list of KEGG
pathway enrichment. (Supplementary Materials)
References
[1] L. Punzi, A. Scanu, R. Ramonda, and F. Oliviero, “Gout as
autoinflammatory disease: new mechanisms for more appro-
priated treatment targets,” Autoimmunity Reviews, vol. 12,
no. 1, pp. 66–71, 2012.
[2] J. Chen, M. Wu, J. Yang, J. Wang, Y. Qiao, and X. Li, “The
immunological basis in the pathogenesis of gout,” Iranian
journal of immunology., vol. 14, no. 2, pp. 90–98, 2017.
[3] C. F. Kuo, M. J. Grainge, W. Zhang, and M. Doherty, “Global
epidemiology of gout: prevalence, incidence and risk factors,”
Nature Reviews Rheumatology, vol. 11, no. 11, pp. 649–662,
2015.
[4] S. K. Rai, J. A. Aviña-Zubieta, N. McCormick et al., “The rising
prevalence and incidence of gout in British Columbia, Can-
ada: population-based trends from 2000 to 2012,” Seminars
in Arthritis and Rheumatism, vol. 46, no. 4, pp. 451–456,
2017.
[5] X. Lu, X. Li, Y. Zhao, Z. Zheng, S. Guan, and P. Chan, “Con-
temporary epidemiology of gout and hyperuricemia in
community elderly in Beijing,” International Journal of Rheu-
matic Diseases, vol. 17, no. 4, pp. 400–407, 2014.
[6] A. Qaseem, R. P. Harris, M. A. Forciea, and for the Clinical
Guidelines Committee of the American College of Physicians,
“Management of acute and recurrent gout: a clinical practice
guideline from the American College of Physicians,” Annals
of Internal Medicine, vol. 166, no. 1, pp. 58–68, 2017.
[7] F. Aslam and C. Michet, “My treatment approach to gout,”
Mayo Clinic Proceedings, vol. 92, no. 8, pp. 1234–1247, 2017.
[8] S. Trelle, S. Reichenbach, S. Wandel et al., “Cardiovascular
safety of non-steroidal anti-inflammatory drugs: network
meta-analysis,” BMJ, vol. 342, no. jan11 1, p. c7086, 2011.
[9] H. J. E. M. Janssens, M. Janssen, E. H. van de Lisdonk, P. L. C.
M. van Riel, and C. van Weel, “Use of oral prednisolone or
naproxen for the treatment of gout arthritis: a double-blind,
randomised equivalence trial,” The Lancet, vol. 371, no. 9627,
pp. 1854–1860, 2008.
[10] H.-Y. Yuan, X.-H. Zhang, X.-L. Zhang, J.-F. Wei, and L. Meng,
“Analysis of patents on anti-gout therapies issued in China,”
Expert Opinion on Therapeutic Patents, vol. 24, no. 5,
pp. 555–572, 2014.
[11] N. Xiao, H. Chen, S. Y. He et al., “Evaluating the efficacy and
adverse effects of clearing heat and removing dampness
method of traditional Chinese medicine by comparison with
Western medicine in patients with gout,” Evidence-based
Complementary and Alternative Medicine, vol. 2018, Article
ID 8591349, 18 pages, 2018.
[12] S.-H. Liu, W.-C. Chuang, W. Lam, Z. Jiang, and Y.-C. Cheng,
“Safety surveillance of traditional Chinese medicine: current
and future,” Drug Safety, vol. 38, no. 2, pp. 117–128, 2015.
[13] S. H. Yu, X. Sun, M. K. Kim et al., “Chrysanthemum indicum
extract inhibits NLRP3 and AIM2 inflammasome activation
via regulating ASC phosphorylation,” J Ethnopharmacol,
vol. 239, p. 111917, 2019.
[14] Y. Zhang, L. Jin, J. Liu et al., “Effect and mechanism of dioscin
from Dioscorea spongiosa on uric acid excretion in animal
model of hyperuricemia,” Journal of Ethnopharmacology,
vol. 214, pp. 29–36, 2018.
[15] M. Napagoda, J. Gerstmeier, H. Butschek et al., “Lipophilic
extracts of Leucas zeylanica, a multi-purpose medicinal plant
in the tropics, inhibit key enzymes involved in inflammation
and gout,” J Ethnopharmacol, vol. 224, pp. 474–481, 2018.
[16] S. P. M. Fischer, I. Brusco, C. Camponogara et al., “Arctium
minus crude extract presents antinociceptive effect in a mice
acute gout attack model,” Inflammopharmacology, vol. 26,
no. 2, pp. 505–519, 2018.
[17] M. Zhou, Y. F. Wang, R. Zhou, M. Zhang, and B. Li, “Treat-
ment of gouty arthritis in different phases by a series of tong-
feng granule: an efficacy observation,” Zhongguo Zhong Xi Yi
Jie He Za Zhi, vol. 33, no. 12, pp. 1603–1607, 2013.
[18] W. Ji, X. X. Zhu, W. F. Tan, and Y. Lu, “Effects of Rebixiao
granules on blood uric acid in patients with repeatedly
15Mediators of Inflammation
attacking acute gouty arthritis,” Chinese Journal of Integrative
Medicine, vol. 11, no. 1, pp. 15–21, 2005.
[19] Y. F. Liu, Y. Huang, C. Wen et al., “The effects of modified
simiao decoction in the treatment of gouty arthritis: a system-
atic review and meta-analysis,” Evidence-Based Complemen-
tary and Alternative Medicine, vol. 2017, Article ID 6037037,
12 pages, 2017.
[20] Y. Wang, L. Wang, E. Li et al., “Chuanhu anti-gout mixture
versus colchicine for acute gouty arthritis: a randomized,
double-blind, double-dummy, non-inferiority trial,” Interna-
tional Journal of Medical Sciences, vol. 11, no. 9, pp. 880–
885, 2014.
[21] E. F. Song, Q. Xiang, K. M. Ren et al., “Clinical effect and action
mechanism of Weicao Capsule (威草胶囊) in treating gout,”
Chinese Journal of Integrative Medicine, vol. 14, no. 2,
pp. 103–106, 2008.
[22] Y. Wang, J. Li, Z. Wang, K. Yang, and inventors; Jinan Univer-
sity, assignee,Medicine for treating gouty arthritis and its prepn
process and application, CHINA patent CN, 2006,
200610037537: A.
[23] W. Wang, T. Liu, L. Yang et al., “Study on the multi-targets
mechanism of triphala on cardio-cerebral vascular diseases
based on network pharmacology,” Biomed Pharmacother,
vol. 116, p. 108994, 2019.
[24] T.-t. Luo, Y. Lu, S.-k. Yan, X. Xiao, X.-l. Rong, and J. Guo,
“Network pharmacology in research of Chinese medicine for-
mula: methodology, application and prospective,” Chinese
Journal of Integrative Medicine, vol. 26, no. 1, pp. 72–80, 2020.
[25] Y. Chen, J. Wei, Y. Zhang et al., “Anti-endometriosis mecha-
nism of Jiawei Foshou San based on network pharmacology,”
Frontiers in Pharmacology, vol. 9, p. 811, 2018.
[26] F. Zhao, L. Guochun, Y. Yang, L. Shi, L. Xu, and L. Yin, “A net-
work pharmacology approach to determine active ingredients
and rationality of herb combinations of Modified-Simiaowan
for treatment of gout,” Journal of Ethnopharmacology,
vol. 168, pp. 1–16, 2015.
[27] H. Liu, J. Wang, W. Zhou, Y. Wang, and L. Yang, “Systems
approaches and polypharmacology for drug discovery from
herbal medicines: an example using licorice,” Journal of Ethno-
pharmacology, vol. 146, no. 3, pp. 773–793, 2013.
[28] D. Szklarczyk, J. H. Morris, H. Cook et al., “The STRING data-
base in 2017: quality-controlled protein-protein association
networks, made broadly accessible,” Nucleic Acids Research,
vol. 45, no. D1, pp. D362–D368, 2017.
[29] Y. Wang, S. Wei, T. Gao et al., “Anti-inflammatory effect of a
TCM formula Li-Ru-Kang in rats with hyperplasia of mam-
mary gland and the underlying biological mechanisms,” Fron-
tiers in Pharmacology, vol. 9, p. 1318, 2018.
[30] D. W. Huang, B. T. Sherman, Q. Tan et al., “DAVID Bioinfor-
matics Resources: expanded annotation database and novel
algorithms to better extract biology from large gene lists,”
Nucleic Acids Research, vol. 35, suppl_2, pp. W169–W175,
2007.
[31] T. J. Coderre and P. D. Wall, “Ankle joint urate arthritis
(AJUA) in rats: an alternative animal model of arthritis to that
produced by Freund’s adjuvant,” Pain, vol. 28, no. 3, pp. 379–
393, 1987.
[32] Y. Chen, H. Yu, F. Guo, Y.Wu, and Y. Li, “Antinociceptive and
anti-inflammatory activities of a standardizedextract of bis-
iridoids from Pterocephalus hookeri,” Journal of ethnophar-
macology, vol. 216, pp. 233–238, 2018.
[33] M. Niwa, A. Nitta, Y. Yamada et al., “Tumor necrosis factor-
alpha and its inducer inhibit morphine-induced rewarding
effects and sensitization,” Biological Psychiatry, vol. 62, no. 6,
pp. 658–668, 2007.
[34] C. C. Chen, A. Zimmer, W. H. Sun, J. Hall, M. J. Brownstein,
and A. Zimmer, “A role for ASIC3 in the modulation of
high-intensity pain stimuli,” Proceedings of the National
Academy of Sciences, vol. 99, no. 13, pp. 8992–8997, 2002.
[35] T. Mosmann, “Rapid colorimetric assay for cellular growth
and survival: application to proliferation and cytotoxicity
assays,” Journal of Immunological Methods, vol. 65, no. 1-2,
pp. 55–63, 1983.
[36] J. Lee and W. Park, “Anti-inflammatory effect of wogonin on
RAW 264.7 mouse macrophages induced with polyinosinic-
polycytidylic acid,” Molecules, vol. 20, no. 4, pp. 6888–6900,
2015.
[37] K. Jayesh, R. Karishma, A. Vysakh, P. Gopika, and M. S. Latha,
“Terminalia bellirica (Gaertn.) Roxb fruit exerts anti-
inflammatory effect via regulating arachidonic acid pathway
and pro-inflammatory cytokines in lipopolysaccharide-
induced RAW 264.7 macrophages,” Inflammopharmacology,
vol. 28, no. 1, pp. 265–274, 2020.
[38] P. Wan, M. Xie, G. Chen et al., “Anti-inflammatory effects of
dicaffeoylquinic acids from Ilex kudingcha on
lipopolysaccharide-treated RAW264.7 macrophages and
potential mechanisms,” Food and chemical toxicology,
vol. 126, pp. 332–342, 2019.
[39] Q. Guo, K. Zheng, D. Fan et al., “Wu-Tou decoction in rheu-
matoid arthritis: integrating network pharmacology and
in vivo pharmacological evaluation,” Frontiers in Pharmacol-
ogy, vol. 8, p. 230, 2017.
[40] Q. Liu, X. H. Xiao, L. B. Hu et al., “Anhuienoside C ameliorates
collagen-induced arthritis through inhibition of MAPK and
NF-κB signaling pathways,” Front Pharmacol, vol. 8, 2017.
[41] A. Sala, E. Proschak, D. Steinhilber, and G. E. Rovati, “Two-
pronged approach to anti-inflammatory therapy through the
modulation of the arachidonic acid cascade,” Biochem
Pharmacol, vol. 158, pp. 161–173, 2018.
[42] L. Li, Y. Zhang, H. Luo et al., “Systematic identification and
analysis of expression profiles of mRNAs and Incrnas in
macrophage inflammatory response,” Shock, vol. 51, no. 6,
pp. 770–779, 2019.
[43] J. Wu, Y. Luo, Q. Jiang et al., “Coptisine from Coptis chinensis
blocks NLRP3 inflammasome activation by inhibiting caspase-
1,” Pharmacological Research, vol. 147, p. 104348, 2019.
[44] Y. Bao, Y. W. Sun, J. Ji et al., “Genkwanin ameliorates
adjuvant-induced arthritis in rats through inhibiting JAK/-
STAT and NF-κB signaling pathways,” Phytomedicine,
vol. 63, p. 153036, 2019.
[45] B. Samuelsson, “Leukotrienes: mediators of immediate hyper-
sensitivity reactions and inflammation,” Science, vol. 220,
no. 4597, pp. 568–575, 1983.
[46] J. H. Evans, D. M. Spencer, A. Zweifach, and C. C. Leslie,
“Intracellular calcium signals regulating cytosolic phospholi-
pase A2 translocation to internal membranes,” Journal of
Biological Chemistry, vol. 276, no. 32, pp. 30150–30160, 2001.
[47] W. L. Smith, D. L. DeWitt, and R. M. Garavito, “Cyclooxy-
genases: structural, cellular, and molecular biology,” Annual
Review of Biochemistry, vol. 69, no. 1, pp. 145–182, 2000.
[48] N. Dalbeth, T. R. Merriman, and L. K. Stamp, “Gout,” The
Lancet, vol. 388, no. 10055, pp. 2039–2052, 2016.
16 Mediators of Inflammation
[49] C. D. Funk, “Prostaglandins and leukotrienes: advances in
eicosanoid biology,” Science, vol. 294, no. 5548, pp. 1871–
1875, 2001.
[50] P. Antonisamy, P. Agastian, C. W. Kang, N. S. Kim, and J. H.
Kim, “Anti-inflammatory activity of rhein isolated from the
flowers of Cassia fistula L. and possible underlying mecha-
nisms,” Saudi Journal of Biological Sciences, vol. 26, no. 1,
pp. 96–104, 2019.
[51] N. Das, A. Bhattacharya, S. Kumar Mandal et al., “Ichnocarpus
frutescens (L.) R. Br. root derived phyto-steroids defends
inflammation and algesia by pulling down the pro-
inflammatory and nociceptive pain mediators: an in-vitro
and in-vivo appraisal,” Steroids, vol. 139, pp. 18–27, 2018.
[52] E. J. Park, Y. M. Kim, H. J. Kim, and K. C. Chang, “Luteolin
activates ERK1/2- and Ca2+-dependent HO-1 induction that
reduces LPS-induced HMGB1, iNOS/NO, and COX-2 expres-
sion in RAW264.7 cells and mitigates acute lung injury of
endotoxin mice,” Inflammation Research, vol. 67, no. 5,
pp. 445–453, 2018.
[53] N. D. Turner, K. J. Paulhill, C. A. Warren et al., “Quercetin
suppresses early colon carcinogenesis partly through inhibi-
tion of inflammatory mediators,” Acta horticulturae, vol. 841,
no. 841, pp. 237–242, 2009.
[54] H. Zeng, S. Dou, J. Zhao et al., “The inhibitory activities of the
components of Huang-Lian-Jie-Du-Tang (HLJDT) on eicosa-
noid generation via lipoxygenase pathway,” Journal of Ethno-
pharmacology, vol. 135, no. 2, pp. 561–568, 2011.
[55] P. Morin, P.-D. St-Coeur, J. Doiron et al., “Substituted caffeic
and ferulic acid phenethyl esters: synthesis, leukotrienes bio-
synthesis inhibition, and cytotoxic activity,” Molecules,
vol. 22, no. 7, pp. 1–7, 2017.
[56] N. S. Prasad, R. Raghavendra, B. R. Lokesh, and K. A. Naidu,
“Spice phenolics inhibit human PMNL 5-lipoxygenase,” Pros-
taglandins, Leukotrienes, and Essential Fatty Acids, vol. 70,
no. 6, pp. 521–528, 2004.
[57] S. Pan, X. Zhao, N. Ji et al., “Inhibitory effect of taxifolin on
mast cell activation and mast cell-mediated allergic inflamma-
tory response,” Int Immunopharmacol, vol. 71, pp. 205–214,
2019.
[58] R. Berra-Romani, P. Faris, S. Negri, L. Botta, T. Genova, and
F. Moccia, “Arachidonic acid evokes an increase in intracellu-
lar Ca2+ concentration and nitric oxide production in endo-
thelial cells from human brain microcirculation,” Cell, vol. 8,
no. 7, p. 689, 2019.
[59] K. K. Reddi and S. D. Tetali, “Dry leaf extracts of Tinospora
cordifolia (Willd.) Miers attenuate oxidative stress and inflam-
matory condition in human monocytic (THP-1) cells,” Phyto-
medicine, vol. 61, p. 152831, 2019.
[60] A. Margalit, K. L. Duffin, A. F. Shaffer, S. A. Gregory, and P. C.
Isakson, “Altered arachidonic acid metabolism in urate crystal
induced inflammation,” Inflammation, vol. 21, no. 2, pp. 205–
222, 1997.
[61] G. G. Graham, M. J. Davies, R. O. Day, A. Mohamudally, and
K. F. Scott, “The modern pharmacology of paracetamol: ther-
apeutic actions, mechanism of action, metabolism, toxicity and
recent pharmacological findings,” Inflammopharmacology,
vol. 21, no. 3, pp. 201–232, 2013.
[62] S. MURAOKA and T. MIURA, “Metabolism of non-steroidal
anti-inflammatory drugs by peroxidase: implication for gas-
trointestinal mucosal lesions,” YAKUGAKU ZASSHI,
vol. 127, no. 4, pp. 749–756, 2007.
[63] H. He, H. Jiang, Y. Chen et al., “Oridonin is a covalent NLRP3
inhibitor with strong anti-inflammasome activity,” Nature
Communications, vol. 9, no. 1, p. 2550, 2018.
[64] Drug and Therapeutics Bulletin, “Latest guidance on the
management of gout,” BMJ, vol. 362, p. 2893, 2018.
[65] C. M. P. G. van Durme, M. D. Wechalekar, and R. B. M. Land-
ewé, “Nonsteroidal anti-inflammatory drugs for treatment of
acute gout,” Journal of the American Medical Association,
vol. 313, no. 22, pp. 2276-2277, 2015.
[66] A. Mohebati, G. L. Milne, X. K. Zhou et al., “Effect of zileuton
and celecoxib on urinary LTE4 and PGE-M levels in smokers,”
Cancer Prevention Research, vol. 6, no. 7, pp. 646–655, 2013.
[67] R. L. Silva, A. H. Lopes, R. O. França et al., “The quassinoid
isobrucein B reduces inflammatory hyperalgesia and cytokine
production by post-transcriptional modulation,” Journal of
Natural Products, vol. 78, no. 2, pp. 241–249, 2015.
17Mediators of Inflammation
